Appointments

Sirona Biochem appoints dermatology expert Dr. Stuart Maddin to its scientifi c advisory board. Dr.

Maddin is clinical professor emeritus at the Department of Dermatology and Skin Science of Dermatology, Faculty of Medicine, University of British Columbia, where he is the director of the Clinical Trials Unit. He has served in an advisory capacity to the Health Protection Branch (Ottawa), U.S. Pharmacopeial Convention (Rockville, MD), Essential Drugs for the World Health Organization (W.H.O. in Geneva) as well as AAD - Therapeutics / FDA Liaison Task Force. Dr. Maddin has also served as a member of the board of Directors of the American Academy of Dermatology, Secretary and president of the Canadian Dermatology Association and also as vice president of the American Dermatology Association. He was the fi rst Canadian to be elected to the International Committee of Dermatology (ICD) and was later appointed as Secretary-General of the ICD (International League of Dermatologic Societies). Dr. Maddin is a founding member of the Regional Dermatology Training Centre in Moshi, Tanzania.

Lorus Therapeutics Inc., a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announces the appointment of Warren Whitehead to its board of directors and chairman of the Audit committee. Mr. Whitehead has held senior fi nancial management positions in several biotechnology and pharmaceutical companies, most recently as chief fi nancial offi cer of ARIUS Research Inc. Prior to that he was CFO at Labopharm Inc. He is currently a member of the board of directors of PlantForm Corporation, a life sciences company that develops biosimilar antibody drugs for treatment of cancer and other critical illnesses.

CO2 Solution Inc. has appointed Thom Skinner as senior vice president fi nance and chief fi nancial offi cer. He will be responsible for fi nancial, accounting and information technology operations as well as the company’s investor relations activities. A career fi nancial executive, Mr. Skinner’s professional experience spans more than 30 years and includes senior fi nancial executive roles in the fi nancial services, manufacturing, pharmaceutical, life sciences and biotech sectors including extensive mergers and acquisition and capital raising work. He joins CO2 Solution from TS Business Solutions, a Québecbased business consultancy which he founded in 2001. In this capacity, he was chief fi nancial offi cer of DiagnoCure Inc., a Québec-based biotechnology company where he managed the company’s successful fi nancial turnaround and secured more than $25 million in new fi nancing on the Toronto Stock Exchange (TSX). He also served as interim vice president (fi nance and information technology) of sanofi aventis Canada. More recently, he acted as principal advisor to the chairman of Groupe Biscuits Leclerc Inc., a major Quebec-based agri-foods company.

Afexa Life Sciences Inc. has appointed William B. White as independent chairman of the board of directors. An experienced global business leader, Mr. White is the retired president of DuPont Canada Company. He has held a variety of global business unit leadership roles in his 34 years with E.I. du Pont de Nemours and Company. Prior to his 2006 appointment as president of DuPont Canada, Mr. White worked across DuPont leading businesses and programs focused on growth through marketing and sales transformation, the development of emerging markets, and step change business strategies. He is currently a partner in CBW Associates, a Canadian business consulting fi rm. A graduate of Purdue University in West Lafayette, Indiana (B.Sc., Mechanical Engineering), he is a 2009 Distinguished Engineering Alumnus and chairs Purdue’s Mechanical Engineering advisory committee. Mr. White also serves on the board of directors of a number of nonprofi t organizations, including the Schulich Center for Responsible Business (York University), MaRS Discovery District, the Ontario Science Centre, and the Sustainable Chemistry Alliance.

Miraculins Inc. has appointed David Howard to its board of directors. Howard is currently the chairman of Angiotech, a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products, and is also a director of Via Pharmaceuticals Inc., Bioasis Technologies Inc, and Methylation Sciences Inc. He is a graduate of the University of Saskatchewan and the Rotman School of Management and the Sauder School of Business in their Director education Programs.

Theralase Technologies Inc. appoints Jorge Córdoba general manager therapeutic division for Theralase’s line of proprietary therapeutic medical laser products. In this role Córdoba will have general management responsibilities over the sales, marketing, production, clinical services and regulatory affairs departments. Córdoba has over 16 years of experience in leading numerous high technology manufacturing companies. His last position, prior to joining Theralase, was as director of operations for a $17 million aerospace organization turnaround situation, in which Mr. Córdoba, through a number of different initiatives, achieved an increase in productivity of over 400 per cent in less than two years. Prior to that, Mr. Córdoba, in the capacity of a Project Operations Manager, successfully launched a 250,000 square foot, $40 million facility for manufacturing high precision assemblies for a division of Magna Inc. Mr. Córdoba obtained a Master’s of Business from the Ivey School of Business, University of Western Ontario in 2005, a Master’s of Science in Advanced Manufacturing Technology from the University of Manchester, Manchester, England in 1993 and a Bachelor of Mechanical-Electrical Engineering from the National University, Mexico City, Mexico in 1989.

real miracle